RT Journal Article
T1 Evaluation of the Predictive Ability, Environmental Regulation and Pharmacogenetics Utility of a BMI-Predisposing Genetic Risk Score during Childhood and Puberty.
A1 Anguita-Ruiz, Augusto
A1 González-Gil, Esther M
A1 Rupérez, Azahara I
A1 Llorente-Cantarero, Francisco Jesús
A1 Pastor-Villaescusa, Belén
A1 Alcalá-Fdez, Jesús
A1 Moreno, Luis A
A1 Gil, Ángel
A1 Gil-Campos, Mercedes
A1 Bueno, Gloria
A1 Leis, Rosaura
A1 Aguilera, Concepción M
K1 Spanish children
K1 childhood
K1 childhood obesity
K1 gene-environment interactions
K1 genetic risk score
K1 genetics
K1 metabolic syndrome
K1 obesity
K1 pharmacogenetics
K1 predictive ability
K1 puberty
AB Polygenetic risk scores (pGRSs) consisting of adult body mass index (BMI) genetic variants have been widely associated with obesity in children populations. The implication of such obesity pGRSs in the development of cardio-metabolic alterations during childhood as well as their utility for the clinical prediction of pubertal obesity outcomes has been barely investigated otherwise. In the present study, we evaluated the utility of an adult BMI predisposing pGRS for the prediction and pharmacological management of obesity in Spanish children, further investigating its implication in the appearance of cardio-metabolic alterations. For that purpose, we counted on genetics data from three well-characterized children populations (composed of 574, 96 and 124 individuals), following both cross-sectional and longitudinal designs, expanding childhood and puberty. As a result, we demonstrated that the pGRS is strongly associated with childhood BMI Z-Score (B = 1.56, SE = 0.27 and p-value = 1.90 × 10-8), and that could be used as a good predictor of obesity longitudinal trajectories during puberty. On the other hand, we showed that the pGRS is not associated with cardio-metabolic comorbidities in children and that certain environmental factors interact with the genetic predisposition to the disease. Finally, according to the results derived from a weight-reduction metformin intervention in children with obesity, we discarded the utility of the pGRS as a pharmacogenetics marker of metformin response.
SN 2077-0383
YR 2020
FD 2020-06-02
LK https://hdl.handle.net/10668/28150
UL https://hdl.handle.net/10668/28150
LA en
DS RISalud
RD Apr 6, 2025